Sphingosine-1-Phosphate Produced by Sphingosine Kinase 1 Promotes Breast Cancer Progression by Stimulating Angiogenesis and Lymphangiogenesis
- 31 January 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (3), 726-735
- https://doi.org/10.1158/0008-5472.can-11-2167
Abstract
Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid mediator that promotes breast cancer progression by diverse mechanisms that remain somewhat unclear. Here we report pharmacologic evidence of a critical role for sphingosine kinase 1 (SphK1) in producing S1P and mediating tumor-induced hemangiogenesis and lymphangiogenesis in a murine model of breast cancer metastasis. S1P levels increased both in the tumor and the circulation. In agreement, serum S1P levels were significantly elevated in stage IIIA human breast cancer patients, compared with age/ethnicity-matched healthy volunteers. However, treatment with the specific SphK1 inhibitor SK1-I suppressed S1P levels, reduced metastases to lymph nodes and lungs, and decreased overall tumor burden of our murine model. Both S1P and angiopoietin 2 (Ang2) stimulated hemangiogenesis and lymphangiogenesis in vitro, whereas SK1-I inhibited each process. We quantified both processes in vivo from the same specimen by combining directed in vivo angiogenesis assays with fluorescence-activated cell sorting, thereby confirming the results obtained in vitro. Notably, SK1-I decreased both processes not only at the primary tumor but also in lymph nodes, with peritumoral lymphatic vessel density reduced in SK1-I–treated animals. Taken together, our findings show that SphK1-produced S1P is a crucial mediator of breast cancer–induced hemangiogenesis and lymphangiogenesis. Our results implicate SphK1 along with S1P as therapeutic targets in breast cancer. Cancer Res; 72(3); 726–35. ©2012 AACR.Keywords
Other Versions
This publication has 38 references indexed in Scilit:
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerJournal of Clinical Oncology, 2010
- Sphingosine 1-phosphate and cancerNature Reviews Cancer, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Estradiol Induces Export of Sphingosine 1-Phosphate from Breast Cancer Cells via ABCC1 and ABCG2Journal of Biological Chemistry, 2010
- Lymphangiogenesis: Molecular Mechanisms and Future PromiseCell, 2010
- Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterningThe Journal of Experimental Medicine, 2009
- Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinomaCancer, 2009
- Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-PhosphateScience, 2009
- Export and functions of sphingosine-1-phosphateBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2009
- Role for sphingosine kinase 1 in colon carcinogenesisThe FASEB Journal, 2008